Sinovac to Host Conference Call to Report 2009 Second Quarter Financial Results

BEIJING, Aug. 11 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of vaccines in China, today announced that it will host a conference call on Wednesday, August 19, 2009 at 8:00 a.m. ET to review the Company's second quarter financial results for the period ended June 30, 2009 and provide an update on recent corporate developments.

To access the conference call, please dial 1-877-407-4018 (USA) or 1-201-689-8471 (international). A replay of the call will be available from 11:00 a.m. ET on August 19, 2009 to September 2, 2009 at midnight. To access the replay, please dial 1-877-660-6853 (USA) or 1-201-612-7415 (international) and reference the account number 3055 and the access code 330444.

A live audio webcast of the call will also be available from the Investors section on the corporate web site at http://www.sinovac.com/ . A webcast replay can be accessed on the corporate website beginning August 19, 2009 and the replay will remain available for 30 days.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(TM), Sinovac's pandemic influenza vaccine (H5N1), has already been approved for government stockpiling. Sinovac is developing vaccines for Enterovirus 71, Universal Pandemic Influenza, Japanese encephalitis vaccine, and Human Rabies vaccine. Its wholly-owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.

For more information, please contact: Contact Information: Helen G. Yang Sinovac Biotech Ltd. Phone: [phone] x871 Fax: [phone] Email: [e-mail] Investors: Amy Glynn/Sara Ephraim The Ruth Group Tel: [phone] Email: [e-mail] [e-mail] Media: Janine McCargo The Ruth Group Tel: [phone] Email: [e-mail]

Sinovac Biotech Ltd.

CONTACT: Helen G. Yang of Sinovac Biotech Ltd., [phone] x871,
fax [phone], [e-mail]; Investors: Amy Glynn & Sara Ephraim,
both of The Ruth Group, [phone] & 7002, [e-mail] &
[e-mail]; Media: Janine McCargo of The Ruth Group,
[phone], [e-mail]

Web Site: http://www.sinovac.com/